Alector, Inc.
ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial forā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.51
Price-6.79%
-$0.11
1Y
Price
Market Cap
$167.648m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1025.5%
EBITDA Margin-1063.4%
Net Profit Margin-997.6%
Free Cash Flow Margin-1025.5%
EBITDA Margin-1063.4%
Net Profit Margin-997.6%
Free Cash Flow MarginRevenue
$18.417m
-31.3%
1y CAGR-18.4%
3y CAGR-22.6%
5y CAGREarnings
-$125.388m
+9.5%
1y CAGR+6.8%
3y CAGR-61.6%
5y CAGREPS
-$1.19
+13.0%
1y CAGR+12.6%
3y CAGR-55.5%
5y CAGRBook Value
$10.382m
$239.916m
Assets$229.534m
Liabilities$34.548m
DebtDebt to Assets
14.4%
-0.3x
Debt to EBITDAFree Cash Flow
-$173.200m
+14.5%
1y CAGR-224.2%
3y CAGR-195.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company